The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Debiopharm Group; Roche; TFS
Travel, Accommodations, Expenses - Merck Serono; Roche
A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
 
Macarena Ines De La Fuente
Consulting or Advisory Role - Agios; FORMA Therapeutics; Foundation Medicine; Puma Biotechnology
Other Relationship - OncLIve (I); Oncology Information Group (I); Targeted Oncology (I)
 
Howard Colman
Consulting or Advisory Role - Abbvie; Bayer; Best Doctors, Inc; Deciphera; FORMA Therapeutics; Innocrin Pharma; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health; Tactical Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma (Inst); BeiGene (Inst); DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Orbus Therapeutics (Inst); Plexxikon (Inst)
 
Mark Rosenthal
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Johnson & Johnson; Lilly/ImClone; Novartis; Pfizer; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly
 
Danijela Levaci
No Relationships to Disclose
 
Tobias Walbert
Consulting or Advisory Role - Orbus Therapeutics; Tocagen
Travel, Accommodations, Expenses - NovoCure; Tocagen
 
Hui Kong Gan
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Eisai; Merck Serono; Merck Serono
Research Funding - AbbVie
 
Maria Vieito
No Relationships to Disclose
 
Mohammed M. Milhem
Honoraria - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Kate Lipford
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Sanjeev Forsyth
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Sylvie Mireille Guichard
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Yelena Mikhailov
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Alexander Sedkov
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Blythe Thomson
Employment - FORMA Therapeutics
Travel, Accommodations, Expenses - FORMA Therapeutics; FORMA Therapeutics
 
Patrick Francis Kelly
Employment - FORMA Therapeutics
Stock and Other Ownership Interests - FORMA Therapeutics
 
Varun Monga
Consulting or Advisory Role - Forma Therapeutics
Research Funding - ImmunoCellular Therapeutics (Inst); Newlink Genetics (Inst); Orbus Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera (Inst); GlaxoSmithKline (Inst)